Explore the words cloud of the IL7sigNETure project. It provides you a very rough idea of what is the project "IL7sigNETure" about.
The following table provides information about the project.
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
|Coordinator Country||Portugal [PT]|
|Total cost||1˙988˙125 €|
|EC max contribution||1˙988˙125 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2015-09-01 to 2020-08-31|
Take a look of project's partnership.
|1||INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES||PT (LISBOA)||coordinator||1˙988˙125.00|
Deregulation of signal transduction is a feature of tumor cells and signaling therapies are gaining importance in the growing arsenal against cancer. However, their full potential can only be achieved once we overcome the limited knowledge on how signaling networks are wired in cancer cells. Interleukin 7 (IL7) and its receptor (IL7R) are essential for normal T-cell development and function. However, they can also promote autoimmunity, chronic inflammation and cancer. We showed that patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive hematological cancer, can display IL7R gain-of-function mutations leading to downstream signaling activation and cell transformation. Despite the biological relevance of IL7 and IL7R, the characterization of their signaling effectors remains limited. Here, we propose to move from the single molecule/pathway-centered analysis that has characterized the research on IL7/IL7R signaling, into a ‘holistic’ view of the IL7/IL7R signaling landscape. To do so, we will employ a multidisciplinary strategy, in which data from complementary high throughput analyses, informing on different levels of regulation of the IL7/IL7R signaling network, will be integrated via a systems biology approach, and complemented by cell and molecular biology experimentation and state-of-the-art in vivo models. The knowledge we will generate should have a profound impact on the understanding of the fundamental mechanisms by which IL7/IL7R signaling promotes leukemia and reveal novel targets for fine-tuned therapeutic intervention in T-ALL. Moreover, the scope of insights gained should extend beyond leukemia. Our in-depth, systems-level characterization of IL7/IL7R signaling will constitute a platform with extraordinary potential to illuminate the molecular role of the IL7/IL7R axis in other cancers (e.g. breast and lung) and pathological settings where IL7 has been implicated, such as HIV infection, multiple sclerosis and rheumatoid arthritis.
|year||authors and title||journal||last update|
F Buontempo, J A McCubrey, E Orsini, M Ruzzene, A Cappellini, A Lonetti, C Evangelisti, F Chiarini, C Evangelisti, J T Barata, A M Martelli
Therapeutic targeting of CK2 in acute and chronic leukemias
published pages: 1-10, ISSN: 0887-6924, DOI: 10.1038/leu.2017.301
Mariana L. Oliveira, Padma Akkapeddi, Isabel Alcobia, Afonso R. Almeida, Bruno A. Cardoso, Rita Fragoso, Teresa L. Serafim, JoÃ£o T. Barata
From the outside, from within: Biological and therapeutic relevance of signal transduction in T-cell acute lymphoblastic leukemia
published pages: 10-25, ISSN: 0898-6568, DOI: 10.1016/j.cellsig.2017.06.011
|Cellular Signalling 38||2019-06-06|
Mariana L. Oliveira, Padma Akkapeddi, Daniel Ribeiro, Alice MelÃ£o, JoÃ£o T. Barata
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update
published pages: , ISSN: 2212-4926, DOI: 10.1016/j.jbior.2018.09.012
|Advances in Biological Regulation||2019-04-18|
Daniel Ribeiro, Alice MelÃ£o, Ruben van Boxtel, Cristina I. Santos, Ana Silva, Milene C. Silva, Bruno A. Cardoso, Paul J. Coffer, JoÃ£o T. Barata
STAT5 is essential for IL-7â€“mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells
published pages: 2199-2213, ISSN: 2473-9529, DOI: 10.1182/bloodadvances.2018021063
|Blood Advances 2/17||2019-04-18|
Alice MelÃ£o, Maureen Spit, Bruno A. Cardoso, JoÃ£o T. Barata
Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity
published pages: 1368-1379, ISSN: 0390-6078, DOI: 10.3324/haematol.2015.141143
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IL7SIGNETURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IL7SIGNETURE" are provided by the European Opendata Portal: CORDIS opendata.